Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088

被引：2
|
作者：
Loong, H. H. F. [1 ]
Daniele, G. [2 ]
Yang, T-Y. [3 ]
Leal, T. A. [4 ]
Goto, K. [5 ]
Shinno, Y. [6 ]
Nishino, K. [7 ]
Sakamoto, T. [8 ]
Felip, E. [9 ]
Ruffinelli, J. C. [10 ]
Gallot, N. [11 ]
Wang, Z. [12 ]
Chen, C. [13 ]
Brennan, B. [13 ]
Pu, S-F. [14 ]
Kornacker, M. [15 ]
Grassi, P. [16 ]
Le, X. [17 ]
Tan, D. S. W. [18 ]
Goh, B-C. [19 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Fdn Policlin Univ Agostino Gemelli IRCC, Phase 1 Unit, Rome, Italy
[3] Taichung Vet Gen Hosp, Chest Med, Taichung, Taiwan
[4] Emory Univ, Hematol & Oncol, Atlanta, GA USA
[5] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan
[6] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[7] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[8] Tottori Univ, Dept Multidisciplinary Internal Med, Div Resp Med & Rheumatol, Tottori, Japan
[9] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[10] Hosp Duran & Reynals, Dept Med Oncol, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain
[11] ClinBAY Ltd, Stat, Limassol, Cyprus
[12] Bayer HealthCare Pharmaceut Inc, Oncol, Cambridge, MA USA
[13] Bayer Healthcare Pharmaceut Inc, Clin Pharmacol, Whippany, NJ USA
[14] Bayer HealthCare Pharmaceut Inc, Benefit Risk Management, Pharmacovigilance, Whippany, NJ USA
[15] Bayer Consumer Care, Early Clin Dev Oncol, Basel, Switzerland
[16] Bayer SpA, RED Oncol, Milan, Italy
[17] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[18] Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore
[19] Natl Univ Canc Inst, Dept Hematol Oncol, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2409
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1320MO
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase III study of zipalertinib plus fi rst-line (1L) platinum- based chemotherapy in patients (pts) with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutations (REZILIENT3): Safety lead-in results
    Kurata, T.
    Fujiwara, Y.
    Naoki, K.
    Viteri, S.
    Inoue, T.
    Hangai, N.
    Wei, L.
    Kawabata, R.
    Wacheck, V.
    Nishio, M.
    ANNALS OF ONCOLOGY, 2024, 35
  • [32] REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations
    Yu, Helena Alexandra
    Besse, Benjamin
    Nishio, Makoto
    Cheng, Ying
    Wei, Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).
    Yu, Helena Alexandra
    Tan, Daniel Shao-Weng
    Smit, Egbert F.
    Spira, Alexander I.
    Soo, Ross A.
    Nguyen, Danny
    Lee, Victor Ho-Fun
    Yang, James Chih-Hsin
    Velcheti, Vamsidhar
    Wrangle, John M.
    Socinski, Mark A.
    Koczywas, Marianna
    Witter, David
    Page, Asher
    Zawel, Leigh
    Janik, John Edward
    Piotrowska, Zofia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
    Ramalingam, S. S.
    Zhou, C.
    Kim, T. M.
    Yang, J. C-H.
    Riely, G. J.
    Mekhail, T.
    Nguyen, D.
    Garcia Campelo, M. R.
    Felip, E.
    Misch, D.
    Kaur, M.
    Bunn, V.
    Lin, M.
    Zhang, P.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1004 - S1004
  • [35] A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
    Huanlan Sa
    Yan Shi
    Chunxia Ding
    Kewei Ma
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7729 - 7742
  • [36] Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions.
    Ou, Sai-Hong Ignatius
    Madison, Russell
    Robichaux, Jacqulyne Ponville
    Ross, Jeffrey S.
    Miller, Vincent A.
    Ali, Siraj Mahamed
    Schrock, Alexa Betzig
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
    Sa, Huanlan
    Shi, Yan
    Ding, Chunxia
    Ma, Kewei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7729 - 7742
  • [38] The landscape of EGFR exon 20 insertion mutations in Chinese patients with non-small cell lung cancer.
    Xu, Shun
    Fu, Zhichao
    CANCER RESEARCH, 2022, 82 (12)
  • [39] Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations
    Li, Jiaqi
    Xie, Mengqing
    Zhao, Ruiying
    Qiang, Huiping
    Chang, Qing
    Qian, Jialin
    Lu, Haijiao
    Shen, Yinchen
    Han, Yuchen
    Su, Chunxia
    Chu, Tianqing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [40] REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
    Nishio, Makoto
    Yu, Helena Alexandra
    Besse, Benjamin
    Cheng, Ying
    Tan, Daniel Shao-Weng
    Wei, Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS219 - TPS219
12345